171 related articles for article (PubMed ID: 25169523)
21. MDM2 SNP309 is an ethnicity-dependent risk factor for digestive tract cancers.
Chen B; Cao L; Hu KW; Zhang JW; Meng XL; Xiong MM
Tumour Biol; 2014 Apr; 35(4):3431-8. PubMed ID: 24338709
[TBL] [Abstract][Full Text] [Related]
22. Correlation between MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility: An updated meta-analysis.
Yin L; Shen G; Zhu B
Thorac Cancer; 2020 Mar; 11(3):672-678. PubMed ID: 31970867
[TBL] [Abstract][Full Text] [Related]
23. MDM2 oncogene, E3 ubiquitin protein ligase T309G polymorphism and risk of oesophageal or gastric cancer: meta-analysis of 15 studies.
Shen W; Hu P; Cao JQ; Liu XX; Shao JH
J Int Med Res; 2014 Oct; 42(5):1065-76. PubMed ID: 25070969
[TBL] [Abstract][Full Text] [Related]
24. MDM2 SNP309T>G polymorphism with hepatocellular carcinoma risk: a meta-analysis.
Liu GY; Jiang DK; Shen SQ; Yu L
Arch Med Res; 2011 Feb; 42(2):149-55. PubMed ID: 21565629
[TBL] [Abstract][Full Text] [Related]
25. The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis.
Cai X; Yang M
J Cancer Res Clin Oncol; 2012 Apr; 138(4):555-61. PubMed ID: 22205265
[TBL] [Abstract][Full Text] [Related]
26. MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis.
Zhao E; Cui D; Yuan L; Lu W
Mol Biol Rep; 2012 Apr; 39(4):3471-7. PubMed ID: 21725850
[TBL] [Abstract][Full Text] [Related]
27. Significant Association of the MDM2 T309G Polymorphism with Breast Cancer Risk in a Turkish Population.
Yilmaz M; Tas A; Donmez G; Kacan T; Silig Y
Asian Pac J Cancer Prev; 2018 Apr; 19(4):1059-1062. PubMed ID: 29699057
[TBL] [Abstract][Full Text] [Related]
28. Association of MDM2 polymorphism with risk and prognosis of leukemia: a meta-analysis.
He X; Chen P; Yang K; Liu B; Zhang Y; Wang F; Guo Z; Liu X; Lou J; Chen H
Acta Haematol; 2015; 133(4):365-371. PubMed ID: 25790771
[TBL] [Abstract][Full Text] [Related]
29. The MDM2 309T>G polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211 controls.
Ma YY; Guan TP; Yao HB; Yu S; Chen LG; Xia YJ; He XJ; Wang HJ; Jiang XT; Tao HQ
PLoS One; 2013; 8(1):e55019. PubMed ID: 23383041
[TBL] [Abstract][Full Text] [Related]
30. Is MDM2 SNP309 Variation a Risk Factor for Head and Neck Carcinoma?: An Updated Meta-Analysis Based on 11,552 Individuals.
Zhuo X; Ye H; Li Q; Xiang Z; Zhang X
Medicine (Baltimore); 2016 Mar; 95(9):e2948. PubMed ID: 26945408
[TBL] [Abstract][Full Text] [Related]
31. The MDM2 309 T/G polymorphism is associated with head and neck cancer risk especially in nasopharyngeal cancer: a meta-analysis.
Zhang Y; Bai Y; Zhang Y; Guan J; Chen L
Onkologie; 2012; 35(11):666-70. PubMed ID: 23147543
[TBL] [Abstract][Full Text] [Related]
32. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis.
Peng Q; Lao X; Chen Z; Lai H; Deng Y; Wang J; Mo C; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
PLoS One; 2013; 8(12):e82773. PubMed ID: 24376578
[TBL] [Abstract][Full Text] [Related]
33. MDM2 T309G polymorphism and esophageal cancer risk: a meta-analysis.
Lei C; Zhang W; Fan J; Qiao B; Chen Q; Liu Q; Zhao C
Int J Clin Exp Med; 2015; 8(8):13413-6. PubMed ID: 26550276
[TBL] [Abstract][Full Text] [Related]
34. Correlations between MDM2 gene SNP309 polymorphism and susceptibility to leukemia.
Ou WB
Med Sci Monit; 2015 Jan; 21():213-8. PubMed ID: 25600314
[TBL] [Abstract][Full Text] [Related]
35. Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls.
Gao J; Kang AJ; Lin S; Dai ZJ; Zhang SQ; Liu D; Zhao Y; Yang PT; Wang M; Wang XJ
Ther Clin Risk Manag; 2014; 10():269-77. PubMed ID: 24790452
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of association between the TP53 Arg72Pro polymorphism and risk of endometriosis based on case-control studies.
Yan Y; Wu R; Li S; He J
Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():1-7. PubMed ID: 25819169
[TBL] [Abstract][Full Text] [Related]
37. Association between MDM2 SNP309 and endometrial cancer risk: A PRISMA-compliant meta-analysis.
Zou X; Zhang Y; Zhang L; Li J; Zhu C; Cheng Q; Zhou J; Chen Y
Medicine (Baltimore); 2018 Dec; 97(49):e13273. PubMed ID: 30544386
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of TP53 (R72P) and MDM2 (T309G) polymorphisms in breast cancer patients.
Yadav P; Masroor M; Tanwer K; Mir R; Javid J; Ahmad I; Zuberi M; Kaza RC; Jain SK; Khurana N; Ray PC; Saxena A
Clin Transl Oncol; 2016 Jul; 18(7):728-34. PubMed ID: 26553387
[TBL] [Abstract][Full Text] [Related]
39. [Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population].
Liu JN; Zhang XM; Guo YL; Sun T; Lin DX; Wen T
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):335-8. PubMed ID: 18953830
[TBL] [Abstract][Full Text] [Related]
40. Polymorphisms in the MDM2 gene and risk of malignant bone tumors: a meta-analysis.
Tang J; Shen L; Song S; An Z; Zhang C
Tumour Biol; 2014 Jan; 35(1):779-84. PubMed ID: 23979978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
